Nadia Zandy
Psychiatric/Mental Health · Philadelphia, PANPI 1164137519
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,102, 6.1 times the $507 reported in 2023. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$814
- AbbVie$765
- Axsome Therapeutics, Inc.$624
- Otsuka America Pharmaceutical, Inc.$569
- Neurocrine Biosciences, Inc.$487
- Alkermes, Inc.$438
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $814 |
| AbbVie | 47 | $765 |
| Axsome Therapeutics, Inc. | 38 | $624 |
| Otsuka America Pharmaceutical, Inc. | 22 | $569 |
| Neurocrine Biosciences, Inc. | 20 | $487 |
| Alkermes, Inc. | 14 | $438 |
| Teva Pharmaceuticals USA, Inc. | 17 | $339 |
| Ironshore Pharmaceuticals Inc. | 14 | $308 |
| Collegium Pharmaceutical, Inc. | 15 | $306 |
| Bausch Health US, LLC | 11 | $234 |
| Lundbeck LLC | 11 | $223 |
| Corium, LLC | 9 | $147 |
| Vanda Pharmaceuticals Inc. | 5 | $127 |
| Johnson & Johnson | 5 | $119 |
| Neos Therapeutics, LP | 5 | $89 |
| Almatica Pharma LLC | 4 | $86 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Harmony Biosciences LLC | 1 | $25 |
| Tris Pharma Inc | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,973 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 21 | $29,564 |
| RexultiBrexpiprazole | 12 | $17,307 |
| Lurasidone Hcl | 20 | $5,378 |
| Aripiprazole | 86 | $4,911 |
| Duloxetine Hcl | 64 | $2,312 |
| Buspirone Hcl | 141 | $1,871 |
| Quetiapine Fumarate | 97 | $1,312 |
| Olanzapine | 81 | $1,311 |
| Divalproex Sodium | 45 | $1,208 |
| Atomoxetine Hcl | 29 | $1,180 |
| Haloperidol | 51 | $1,172 |
| Trazodone Hcl | 140 | $1,006 |
| Carbamazepine | 19 | $938 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $766 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $765 | $29,56421 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $569 | $17,30712 claims |
| Almatica Pharma LLCSertraline Hcl | $86 | $42988 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Philadelphia
- Andrew RenziPhiladelphia$13K
- Clement JohnPhiladelphia$13K
- Rena LindenPhiladelphia$9K
- Gordon ZeisPhiladelphia$8K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.